The Mayo Clinic Cancer Center (MCCC) oversees the scientific aspects of cancer clinical trials conducted at Mayo Clinic through the Center's Protocol Review and Monitoring System (PRMS). Responsibilities of the PRMS are independent and non-overlapping with those of the Mayo IRB and those with responsibilities specific to Data and Safety Monitoring activities. The focus of the PRMS is on scientific merit, priorities, and progress of the clinical research protocols conducted at the MCCC. Due to the volume of studies and significant differences in study population, scientific review is accomplished through one of the Center's two scientific review committees, the Scientific Review Committee (SRC) A and B. The SRC-A reviews all interventional hematologic malignancy studies;the SRC-B reviews ail other interventional studies. To ensure consistency across committees, each committee adheres to the same policies and procedures and has ultimate responsibility for the approval/disapproval of each study as well as the final decision concerning prioritization. Dr. Henry Pilot provides overall leadership and expertise to the PRMS. The SRC committees are chaired by Drs. Thomas Witzig (SRC-A: interventional hematologic malignancy studies) and Timothy Hobday (SRC-B: all other interventional studies). The scientific review committees have the authority to approve/defer/disapprove protocols and subsequent amendments and modifications that meet the scientific merit and scientific priorities of the MCCC. In addition, these committees have the authority to close any protocol due to insufficient or poor accrual.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682949
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$95,622
Indirect Cost
$35,541
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44

Showing the most recent 10 out of 948 publications